Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/
我們正在追蹤 Teva Pharmaceuticals 的市場擴張
過去 90 日內有 66 個訊號。
Teva Pharmaceuticals 的國際擴張與競爭對手的比較
Teva Pharmaceuticals你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Teva Pharmaceuticals你 | 0 | 0 | — | 0 | 0 |
Quality Control Analyst I
查看招聘Kfar Saba, Center District, Israel · 前日
Sr Director Supply Chain
查看招聘Dupnitsa, Kyustendil, Bulgaria · 3日前
Manager, Category Excellence / Capability Lead ExM GP
查看招聘Sofia, Sofia City, Bulgaria · 3日前
Today, we announced Teva Pharmaceuticals’ Q1 2026 financial results, marking a strong start to the year and reinforcing our transformation into a leading biopharma company.Our key innovative products are becoming an engine of sustainable growth, collectively growing 41% year-over-year in local currency and continuing to shift Teva’s portfolio mix. We also saw continued progress on our late-stage innovative pipeline and stable generics performance driven by biosimilars growth. That's what our Piv ...
進行中
Explore open roles at Teva India >>
進行中
This post is directed to HCPs only.Looking for expert perspectives on the evolving role of long-acting injectables (LAIs) in improving the lives of people living with schizophrenia?Come along to the Forum Hall at 13.15 on Sunday 29th March during EPA 2026 in Prague to hear from an expert faculty as they consider the evolving evidence, opinion and guidelines supporting the wider integration of LAIs into clinical practice.13.15-14.15, Forum Hall (second floor)https://lnkd.in/eqRnEUpf Please do n ...
已結束特拉維夫證券交易所上漲，Tower Semiconductor和Teva領漲。以色列聯合銀行在高成交量下下跌。
梯瓦製藥在連續三年增長後，預計2026年收入和利潤將下降，預期收入為164-168億美元，每股收益為2.55-2.65美元。
Teva製藥的API部門將在兩年內於以色列裁減250個職位,作為營運調整的一部分,主要影響貝爾謝巴附近的Neot Hovav工廠。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Teva Pharmaceuticals 業務、市場及增長訊號的快速解答。
